Higher Levels of Lipoprotein Associated Phospholipase A2 is associated with Increased Prevalence of Cognitive Impairment: the APAC Study.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a unique circulating phospholipase with inflammatory and oxidative activities and the limited data regarding the relationship between Lp-PLA2 and cognitive impairment are conflicted. We conducted a cross-sectional study including 1,374 Chinese adults recruited from 2010 to 2011, aiming to evaluate the relationship between Lp-PLA2 levels and the prevalence of cognitive impairment in a Chinese community-based population. Participants underwent standardized evaluation. Serum Lp-PLA2 mass was measured by ELISA. Cognition status was evaluated via the Mini-Mental Status Exam (MMSE) and cognitive impairment was identified as MMSE <24. Multivariable logistic regression models were used to assess the associations of Lp-PLA2 mass with cognitive impairment. Lp-PLA2 mass was significantly associated with the prevalence of cognitive impairment after adjusting for other potential confounding factors (compared with the first quartile, adjusted ORs of the second, third, and fourth quartile were 2.058 (95% CI, 0.876-4.835), 2.834 (95% CI, 1.255-6.398), and 4.882 (95% CI, 2.212-10.777), p < 0.0001). In conclusion, elevated level of Lp-PLA2 mass was independently associated with the prevalence of cognitive impairment in Chinese adults.
Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.|Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100050, China.|Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, 100050, China.
Ruixuan
R
Jiang
Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.|Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100050, China.|Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, 100050, China.
Shengyun
S
Chen
Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.|Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100050, China.|Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, 100050, China.
Yuan
Y
Shen
Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.|Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100050, China.|Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, 100050, China.
Jianwei
J
Wu
Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan, 063000, China.
Shuohua
S
Chen
Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.|Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100050, China.|Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, 100050, China.|Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, 100050, China.
Anxin
A
Wang
Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan, 063000, China.
Shouling
S
Wu
Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.|Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100050, China.|Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, 100050, China.
Xingquan
X
Zhao
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000328:Adult; D000368:Aged; D044466:Asian People; D002681:China / Q000453:epidemiology; D060825:Cognitive Dysfunction / Q000097:blood* / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C526684:PLA2G7 protein, human